Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon

Jose E Gallegos; Dani C Inglesby; Zachary T Young; Fernando A Herrera

doi:10.1016/j.jhsa.2020.07.009

Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon

J Hand Surg Am. 2021 Jan;46(1):54-59. doi: 10.1016/j.jhsa.2020.07.009. Epub 2020 Sep 16.

Authors

Jose E Gallegos¹, Dani C Inglesby¹, Zachary T Young², Fernando A Herrera³

Affiliations

¹ College of Medicine, Medical University of South Carolina, Charleston, SC.
² College of Medicine, Medical University of South Carolina, Charleston, SC; Division of Plastic and Reconstructive Surgery, Medical University of South Carolina, Charleston, SC.
³ College of Medicine, Medical University of South Carolina, Charleston, SC; Division of Plastic and Reconstructive Surgery, Medical University of South Carolina, Charleston, SC; Department of Surgery, Ralph H Johnson Veterans Affairs Medical Center, Charleston, SC. Electronic address: herreraf@musc.edu.

PMID: 32948347
DOI: 10.1016/j.jhsa.2020.07.009

Abstract

Raynaud phenomenon (RP) is a condition causing vasospasm in the fingers and toes of patients that can have a significant negative impact on quality of life. This can lead to pain, ulceration, and possible loss of digits. Several pharmacological options are available for treatment. However, RP can often be refractory to traditional modalities, leaving surgery or injections as the next available options. This article provides a review and update on the use of botulinum toxin as an effective therapy for the treatment of RP refractory to medical management.

Keywords: BOTOX; Dysport; Raynaud; botulinum toxin; vasospasm.

Publication types

Review

MeSH terms

Botulinum Toxins, Type A* / therapeutic use
Fingers
Humans
Neuromuscular Agents* / therapeutic use
Quality of Life
Raynaud Disease* / drug therapy

Substances

Neuromuscular Agents
Botulinum Toxins, Type A